Almirall: positive results in actinic keratosis
(CercleFinance.com) - Spanish drugmaker Almirall and US partner Athenex said that they have attained positive top-line results in two studies for KX2-391 in actinic keratosis, a common skin condition that results in patches of thick, scaly or crusty skin.
Both Phase III studies achieved their primary endpoints, defined as 100% clearance of the lesions at day 57 within the face or scalp treatment areas.
Results show that 44% and 54% of patients achieved 100% actinic keratosis lesion clearance, the companies said.
Actinic keratosis is the most common pre-cancerous condition in dermatology. It affects 55 million Americans.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Both Phase III studies achieved their primary endpoints, defined as 100% clearance of the lesions at day 57 within the face or scalp treatment areas.
Results show that 44% and 54% of patients achieved 100% actinic keratosis lesion clearance, the companies said.
Actinic keratosis is the most common pre-cancerous condition in dermatology. It affects 55 million Americans.
Copyright (c) 2019 CercleFinance.com. All rights reserved.